DNTH vs LEN
Dianthus Therapeutics Inc. (DNTH) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
LEN does not have a complete income-statement cache yet.
DNTH currently screens at market cap $4.40B. LEN currently screens at market cap $0.
Not investment advice. Open the DNTH and LEN stock pages for the full models.
Not investment advice.